2026-09-17
Tim F. Greten, Mitchell Ho
A new chimeric antigen receptor (CAR) T cell product consists of autologous T cells expressing an affinity-tuned glypican 3-targeted CAR and armoured to secrete a dominant-negative TGFβ receptor II. This cell product was tested in 36 patients with hepatocellular carcinoma and, although the initial efficacy results were promising, antigen loss and limited progression-free survival remain concerns. Here we discuss what else is needed to bring CAR T cells for solid tumours into the clinic.
DOI: 10.1038/s41571-026-01206-22026-09-17
Kathleen N. Moore, Oladapo O. Yeku, Brooke E. Howitt, Hagop Youssoufian, Joyce F. Liu
DOI: 10.1038/s41571-026-01208-02026-09-16
Diana Romero
DOI: 10.1038/s41571-026-01207-12026-09-11
William Jia, Ronghua Zhao, Howard L. Kaufman, Robert L. Martuza
DOI: 10.1038/s41571-026-01205-32026-09-07
Peter Sidaway
DOI: 10.1038/s41571-026-01202-62026-09-03
William Jia, Ronghua Zhao, Howard L. Kaufman, Robert L. Martuza
The development of diverse immunotherapeutic modalities has revolutionized the treatment of cancer but the effectiveness of these therapies remains restricted by fundamental mechanistic limitations relating to the generation of tumour-specific T cells, and their activation and/or access into the tumour microenvironment. In this Perspective, the authors position oncolytic viruses as a foundational immuno-oncology platform for systemic immune reprogramming to simultaneously overcome these availability, activation and admission barriers, and delineate four pillars for the development of a new generation of oncolytic virotherapies.
DOI: 10.1038/s41571-026-01198-z2026-08-27
Peter Sidaway
DOI: 10.1038/s41571-026-01200-82026-08-26
Monireh Sadat Seyyedsalehi, Paolo Boffetta
The global cancer burden is projected to rise substantially in the coming decades, driven largely by population growth and ageing. Yet cancer patterns and outcomes vary widely across regions, reflecting differences in exposures, healthcare capacity and access to care. Translating these evolving epidemiological patterns into effective and equitable cancer-control strategies is increasingly urgent.
DOI: 10.1038/s41571-026-01199-y